Skip to main content
SpringerLink
Log in

Nouveaux traitements médicaux des cancers digestifs

  • Chapter
Book cover Les cancers digestifs

Part of the book series: Oncologie Pratique ((ONCOLPRAT))

  • 312 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Druker BJ, Imatinib As a Paradigm of Targeted Therapies (2003) J Clin Oncol 21: 239–45

    Google Scholar 

  2. Gray R, Giantonio BJ, O‘Dwyer PJ et al. (2003) The safety of adding angiogenesis inhibition into treatment for colorectal, breast and lung cancer: the eastern cooperative oncology group’s (ECOG) experience with bavacizumab. Proc Am Soc Clin Oncol 22: A825

    Google Scholar 

  3. Herbst RS, Maddox AM, Rothenberg ML et al. (2002) Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 20: 3815–25

    CAS  PubMed  Google Scholar 

  4. Lassau N, Koscielny S, Opolon P (2001) Evaluation of contrast-enhanced color doppler ultrasound for the quantification of angiogenesis in vitro. Invest Radiol 36: 50–5

    CAS  PubMed  Google Scholar 

  5. Eder JP, Supko JG, Clark JW et al. (2002) Phase I of clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 20: 3772–84

    Article  CAS  PubMed  Google Scholar 

  6. Albanell J, Rojo F, Averbuch S et al. (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. 20: 110–24

    Article  CAS  PubMed  Google Scholar 

  7. Rowinski EK (2003) Challenges of developing therapeutics that target signal transduction in patients with gynaecologic and other malignancies J Clin Oncol 21: 175–86

    Google Scholar 

  8. Rosner GL, Stadler W, Ratain MJ (2002) Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 20: 4478–84

    Article  CAS  PubMed  Google Scholar 

  9. Cunningham D, Humblet Y, Siena S (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N Engl J Med 351: 337–45

    Article  CAS  PubMed  Google Scholar 

  10. Xiong HQ, Rosenberg A, Lobuglio A et al. (2004) Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 22: 2610–6

    Article  CAS  PubMed  Google Scholar 

  11. Hurwitz H, Fehrenbacher L, Novotny W et al. (2004) Bevazicumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–42

    Article  CAS  PubMed  Google Scholar 

  12. Giaccone G, Herbst RS, Manegold C et al. (2004) Gefitinib in Combination With gemcitabine and Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial-INTACT 1. J Clin Oncol 22: 785–94

    Article  PubMed  Google Scholar 

  13. Herbst RS, Giaccone G, Schiller JH et al. (2004) Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial-INTACT 2. J Clin Oncol 22: 785–94

    Article  CAS  PubMed  Google Scholar 

  14. Van Oosterom AT, Judson I, Verwej J et al. (2001) STI 571, an active drug in metastatic gastrointestinal stromal timors (GIST), an EORTC phase I study. Proc Am Soc Clin Oncol 20: Abstract 2

    Google Scholar 

  15. Van Oosterom AT, Judson I, Verwej J et al. (2002) Update of the imatinib (STI 571, Glivec) phase I study in gastrointestinal stromal tumors (GISTs) Proc Am Soc Clin Oncol 21: Abstract 327

    Google Scholar 

  16. Demetri GD, Rankin C, Fletcher C et al. (2002) Phase III dose-randomized study of imatinib mesylate (Gleevec, STI 571) for GIST: Intergroup S0033 early results. Proc Am Soc Clin Oncol 21: Abstract 1651

    Google Scholar 

  17. Aswad B, Constantinou M, Ianniti D et al. (2002) C-Kit is a potential target for biliary carcinomas. Proc Am Soc Clin Oncol 21: Abstract pp2227

    Google Scholar 

  18. Demetri GD, George S, Heinrich MC et al. (2003) Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate. Proc Am Soc Clin Oncol 22: Abstract 3273

    Google Scholar 

  19. Braun AD, Hilger R (2002) The EFGR inhibitor ZD1839 restored sensitivity to SN38 treatment in chemotherapy-resistant colorectal cancer cells in vitro. Program and abstract of 14th EORTC-NCI-AACR symposium on molecular targets and cancer therapeutics

    Google Scholar 

  20. Dorligschaw O, Kegel T, Jordan K et al. (2003) ZD 1839 (IRESSA)-based treatment as lastline therapy in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 22: Abstract 1494

    Google Scholar 

  21. Cho CD, Fischer GA, Halsey J et al. (2003) A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with unresectable or metastatic colorectal cancer. Proc Am Soc Clin Oncol 22: Abstract 1062

    Google Scholar 

  22. Schiller JH (2003) New directions for ZD1839 in the treatment of solid tumors. Semin Oncol 30(suppl 1): 49–55

    CAS  PubMed  Google Scholar 

  23. Moore MJ, Goldstein D, Hamm J et al. (2005) Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Proc Am Soc Clin Oncol 24: Abstract 1

    Google Scholar 

  24. Saltz L, Rubin M, Hochster H et al. (2001) Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20: Abstract 7

    Google Scholar 

  25. Erbitux (IMC-C225) plus weekly irinotecan (CPT11), fluoro-uracil (5-FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 21: Abstract 536

    Google Scholar 

  26. Meropol NJ, Berlin J, Hecht JR et al. (2003) Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 22: Abstract 1026

    Google Scholar 

  27. Gordon MS, Margolin K, Talpaz M et al. (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth in patients with advanced cancer. J Clin Oncol 19: 843–50

    CAS  PubMed  Google Scholar 

  28. Gianantonio BJ, Levy D, Catalano PJ et al. (2002) Incorporating angiogenesis inhibition with bevacizumab (anti-VEGF) into frontline chemotherapy with irinotecan (CPT11), fluoro-uracil and leucovorin (FU/LV) for advanced colorectal cancer (advCRC): a toxicity analysis of ECOG study E2200. Proc Am Soc Clin Oncol 21: Abstract 503

    Google Scholar 

  29. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. (2003) Phase II, Randomized Trial Comparing Bevacizumab Plus Fluoro-uracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer. J Clin Oncol 21: 60–5

    CAS  PubMed  Google Scholar 

  30. Saltz L, Cox JV, Blanke C et al. (2000) Irinotecan plus fluorouracil ande leucovorin for metastatic colorectal cancer. N Engl J Med 343: 905–14

    Article  CAS  PubMed  Google Scholar 

  31. Giantonio BJ, Levy P, O‘Dyer P et al. (2003) Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (ADVCRC): results from the eastern cooperative oncology group (ECOG) study E2200. Proc Am Soc Clin Oncol 22: Abstract 1024

    Google Scholar 

  32. Kindler HL, Ansari L, Lester E et al. (2003) Bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 22: Abstract 1037

    Google Scholar 

  33. Traxler P (2004) From drug discovery to the clinic: the story of the VEGFR tyrosine kinase inhibitor PTK787/ZK222584. Program and abstracts of the 9th Annual World Congress Drug Discovery Technology; August 8-13; Boston, Massachusetts

    Google Scholar 

  34. Hecht JR, Trarbach T, Jaeger E et al. (2005) A randomized double-blind placebo controlled, phase III study in patients (pts) with metastatic adenocarcinoma of the colon or rectum receiving first line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK/ZK 222584 or placebo (CONFIRM-1). Proc Am Soc Clin Oncol 24: Abstract 3

    Google Scholar 

  35. Burch PA, Alberts SR, Schroeder MT et al. (2003) Gemcitabine and ISIS-2503 for patients with pancreatic adenocarcinoma: a north central cancer treatment group phase II study. Proc Am Soc Clin Oncol 22: Abstract 1038

    Google Scholar 

  36. Van Custem E, Kasarek P, Oettle H et al. (2002) Phase III comparing gemcitabine + R115777 (Zarnestra®) versus gemcitabine + placebo in advanced pancreatic cancer. Proc Am Soc Clin Oncol 21: Abstract 517

    Google Scholar 

  37. Mac Donald JS, Chansky K, Withehead R et al. (2002) A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer. A SWOG study. Proc Am Soc Clin Oncol 21: Abstract 548

    Google Scholar 

  38. Cunningham D, De Gramont A, Scheithauer W et al. (2002) Randomized double-blind placebo-controlled trial of the farnesyl transferase inhibitor R115777 (Zarnestra®) in advanced refractory colorectal cancer. Proc Am Soc Clin Oncol 21: Abstract 502

    Google Scholar 

  39. Strumberg D, Bauer RJ, Moeller JG et al. (2002) Final result of a phase I pharmacocinetic and pharmacodynamic study of the raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Proc Am Soc Clin Oncol 31a: Abstract 121

    Google Scholar 

  40. Lorusso PM, Adjei JM, Meyer MB et al. (2002) A phase I clinical and pharmacokinetic evaluation of the oral MEK inhibitor CI-1040 administered for 21 consecutive days repeated 4 weeks in patients with advanced cancer. Proc Am Soc Clin Oncol 21: Abstarct 321

    Google Scholar 

  41. Richards D, Waterhouse D, Wagener D et al. (2002) Randomized double-blind placebocontrolled phase 2 study of the histone deacetylase inhibitor CI-994 plus gemcitabine (CI-994plusG) versus placebo plus gemcitabine (PplusG) in the treatment of patients with advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol 21: Abstract 162a

    Google Scholar 

  42. Schwartz GK, Ilson D, Saltz L et al. (2001) Phase II study of the cyclin-dependant kinase inhibitor administered to patients with advanced gastric cancer. J Clin Oncol 19: 1985–92

    CAS  PubMed  Google Scholar 

  43. Motwani M, Jung C, Sirotnak FM et al. (2001) Augmentation of apoptosis and tumor regressions by flavopiridol in the presence of CPT11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res 7: 4209–19

    CAS  PubMed  Google Scholar 

  44. Shah MA, Kortmansky J, Gonen M et al. (2002) A phase I/pharmacologic study of weekly sequential irinotecan (CPT) and flavopiridol (F). Proc Am Soc Clin Oncol 21: Abstract 373

    Google Scholar 

  45. Tsujii M, Kawano S, Tsuji S et al. (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705–15

    Article  CAS  PubMed  Google Scholar 

  46. Blanke CD, Benson AB, Dragovich T et al. (2002) A phase II of celecoxib (CX), irinotecan (I), 5-fluorouracil (5-FU) and leucovorin (LV) in patients (pts) with unresectable or metastastic colorectal cancer (CRC). Proc Am Soc Clin Oncol 21: Abstract 505

    Google Scholar 

  47. King J, Clingan P, Morris DL et al. (2002) Placebo control double-blind randomised clinical trial of the matrix metalloprotease inhibitor (MMP) marimastat in patients with inoperable colorectal cancer liver metastases (CRCLM): significant survival advantage in patients with musculoskeletal symptoms. Proc Am Soc Clin Oncol 21: Abstract 537

    Google Scholar 

  48. Foon KA, John WJ, Chakraborty M et al. (1999) Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 17: 2889–95

    CAS  PubMed  Google Scholar 

  49. Bhatnagar A, Carmichael J, Cosgriff T et al. (2003) A randomized double-blind placebo controlled phase III study of monoclonal antibody 3H1 plus 5-fluorouracil (5-FU)/leucovorin (LV) in stage IV colorectal carcinoma. Proc Am Soc Clin Oncol 22: Abstract 1041

    Google Scholar 

  50. Seva C, Dickinson CJ, Tamada T (1994) Growth-promoting effects of glycine-extended progastrin. Science 265: 410–2

    CAS  PubMed  Google Scholar 

  51. Hecht JR, Ajani JA, Michaeli D (2002) Phase II study of G17DT immunogen in combinaison with cisplatin (CDDP) and 5-fluorouracil (5-FU) in subjects with metastatic or locally recurrent gastric and gastroesophagal cancer previously treated with chemotherapy for advanced disease. Proc Am Soc Clin Oncol 154: Abstract 613

    Google Scholar 

  52. Hecht JR, Ajani JA, Michaeli D (2003) A multicenter phase II study of cisplatin (CDDP) and 5-fluorouracil (5-FU) in combinaison with G17DT immunogen in patients with metastatic adenocarcinoma of the stomach or gastroesophagal junction previously untreated with chemotherapy for advanced disease. Proc Am Soc Clin Oncol 22: Abstract 1035

    Google Scholar 

  53. Shapiro J, Marshall J, Karasek A et al. (2005) G17DT plus gemcitabine (gem) versus gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: results of a randomized, double blind, multinational multicenter study. Proc Am Soc Clin Oncol 24: Abstract 4012

    Google Scholar 

  54. Haller DG (2001) Update of clinical trials with edrecolomab: a monoclonal antibody therapy for colorectal carcinoma. Semin Oncol 26(suppl. 1): 25–30

    Google Scholar 

  55. Fields AL, Keller AM, Schwartzberg L et al. (2002) Edrecolomab (17-1A antibody)(EDR) in combination with 5-fluoro-uracil (FU) based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomized North American phase III study. Proc Am Soc Clin Oncol 21: Abstract 508

    Google Scholar 

  56. Hannah N, Chung T, Hecht JR et al. (2003) TNFerade in pancreatic cancer: preliminary results of the dose-escalating phase of a major randomized study in patients with locally advanced pancreatic cancer. Proc Am Soc Clin Oncol 22: Abstract 1086

    Google Scholar 

  57. Reid TR, Sze D, Galanis E et al. (2003) Intra-arterial administration of a replication-selective adenovirus ONYX-015 in patients with colorectal carcinoma metastatic to the liver: safety, feasibility and biologic activity. Proc Am Soc Clin Oncol 22: Abstract 793

    Google Scholar 

  58. Ribas A, Butterfield LH, Glaspy JA, Economou JS (2003) Current Developments in Cancer Vaccines and Cellular Immunotherapy. J Clin Oncol 21: 2415–32

    Article  CAS  PubMed  Google Scholar 

Download references

Authors
  1. J. Ezenfis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag France

About this chapter

Cite this chapter

Ezenfis, J. (2006). Nouveaux traitements médicaux des cancers digestifs. In: Les cancers digestifs. Oncologie Pratique. Springer, Paris. https://doi.org/10.1007/2-287-30874-1_15

Download citation

  • DOI: https://doi.org/10.1007/2-287-30874-1_15

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-22087-6

  • Online ISBN: 978-2-287-30874-1

Publish with us

Policies and ethics

Search

Navigation